Our research is interdisciplinary at the interface of mathematics & pharmacy. This includes development of
- new mathematical/statistical approaches, incl. model reduction of complex biological networks like the blood coagulation system and the epidermal growth factor receptor signalling cascade, or non-parametric goodness-of-fit testing for parametric covariate models
- mathematical models for systems of pharmacological interest, incl. mechanistic models of bacterial growth under antibiotic actions, 3d models of endothelial cell morphology and blood flow interaction, cell-level models of inflammatory bowel diseases and their treatment options, or physiologically-based pharmacokinetic models for small molecules & therapeutic proteins
- software development, incl. a MATLAB toolbox to support modelling and analysis in pharmacokinetics/-dynamics
as well as
- analyses of experimental data from drug research and (pre-) clinical development, incl. special populations (obese, or pediadrics), special therapeutics (monoclonocal antibodies, CAR-T cell therapies), special indications (oncology, inflammation),
- toxicokinetics of aluminium as vaccine adjuvant
- optimising therapies by model-informed precision dosing (IMPD), e.g., by combining data assimilation and reinforcement learning, or by implementing IMPD in clincial practice
We are not dogmatic about the employed mathematical & statistical approaches. At the core are deterministic & stochastic models of dynamical systems (ordinary differential equations, differential-algebraic systems, Markov processes) and hierarchical statistical models (frequentist and Bayesian). But we also link in to control theory or Boolean network models.
Our research is supported by several third-party funding schemes, most importantly within the larger projects
In addition, funding is based on individual research projects, e.g., on
- model based assessment of aluminium concentrations in rat & human with the Paul-Ehrlich-Institute (PEI), Germany
- transport mediated uptake clearance with the Bayer Pharma AG
- adaptation and optimisation of dosing strategies of a mAb with Merck KGaA
The group members typically span a range of disciplines, incl. mathematics, bioinformatics/systems biology, physics or pharmacy.
